louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04759937: Immunochromatography Versus Microscopy for Diagnosis of Entamoeba Histolytica/Dispar Infection.
Official title: Immunochromatography Versus Microscopy for Diagnosis of Entamoeba Histolytica/Dispar Infection in Sohag.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Dysentery Amebic
Keywords: dysentery
diarrhea
Entamoeba
histolytica
dispar
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2021-02-18
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: samples will be collected from outpatients complaining of dysentery or diarrhea with any age \& sex groups from different locations (cities and village).

Brief summary: Amoebiasis, an infection by the protozoan parasite Entamoeba histolytica is globally considered as the third leading parasitic cause of human mortality besides malaria and schistosomiasis. It is estimated that E. histolytica may infect half a billion people annually. Moreover, it was estimated that 100,000 patients per year died due to the clinical complications of the disease. Laboratory diagnosis of E. histolytica/dispar is usually achieved by microscopic detection of trophozoites or cysts in stool samples. Microscopy is time consuming and requires an experienced observer to identify the organism. Furthermore, it must be performed on three stool samples to increase sensitivity leading to decreased patient compliance and delay in the final diagnosis. Therefore, a few the commercially available copro-antigen assay have been developed for E. histolytica/dispar diagnosis including the enzyme immunoassay and non-enzymatic immunochromatographic (ICT) assays that do not depend on microscopy skills and increase laboratory efficiency by reducing time and cost.

The aim of the study is:

1. to evaluate the efficacy of commercially available rapid immunochromatographic Copro-antigen assay (RIDA® QUICK Entamoeba) in comparison with conventional microscopic examination for the diagnosis of E. histolytica /dispar infection.
2. to estimate the prevalence of E. histolytica /dispar infection in outpatients in Sohag.


Eligibility criteria: Inclusion Criteria:

* Patients complaining of dysentery or diarrhea with any age \& sex groups.

Exclusion Criteria:

* Patients taking amoebicidal drugs.

Primary outcomes:
measure: evaluate the efficacy of immunochromatographic Copro-antigen assay for diagnosis of Entamoeba histolytica/ dispar.
timeFrame: 16 weeks following the startpoint of the study.
Secondary outcomes:
measure: detect the prevelance of Entamoeba histolytica/ dispar in Sohag.
timeFrame: 16 weeks following the startpoint of the study.
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Faculty of medicine-Sohag University
Study officials:
References:
Clinical trial NCT01793337: Core Body Temperature Measurement During Hot and Cold Environmental Exposure
Official title: Tympanic and Frontal Versus Oesophageal Core Temperature Reading During Hot and Cold Environmental Exposure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Body Temperature
Hypothermia
Lead sponsor: Institute of Mountain Emergency Medicine
Sponsor class: OTHER
Collaborators: name: Medical University Innsbruck
First posted: 2013-02-15
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: Accurate measurement of core body temperature at the scene of an accident is critical for both diagnosis and treatment/triage decisions for hypothermic patients. Measurement in the lower third of the oesophagus is considered the gold standard of CT reading, but invasive and hardly applicable with a conscious patient. Tympanic membrane sensors for CT reading have been widely tested by may be unreliable in extreme environmental temperatures. Similarly, the Double Sensor device is a non-invasive device and is promising for prehospital use but has not been sufficiently verified under very cold and hot environmental conditions. Furthermore, comparisons of different non-invasive methods with oesophageal measurement in extreme conditions are lacking. The objective of these studies is to compare different techniques of core body temperature measurement with exposure to cold and hot environments.


Eligibility criteria: Inclusion Criteria:

* \>18 years old
* ASA class 1

Exclusion Criteria:

* \<18 years old
* American society of anesthesiologists class \>1
* history of ear, nose, throat surgery
* congenital malformation of head/throat/ear/nose
* absence of informed consent

Primary outcomes:
measure: Difference between oesophageal and epitympanic temperature
timeFrame: 10 min measurment at +20 °C followed by 10 min measurment at -20 °C
Secondary outcomes:
Other outcomes:
Locations:
city: Bolzano
country: Italy
facility: Eurac research
state: Provincia autonoma di Bolzano
Study officials:
References:
citation: Gunga HC, Werner A, Stahn A, Steinach M, Schlabs T, Koralewski E, Kunz D, Belavy DL, Felsenberg D, Sattler F, Koch J. The Double Sensor-A non-invasive device to continuously monitor core temperature in humans on earth and in space. Respir Physiol Neurobiol. 2009 Oct;169 Suppl 1:S63-8. doi: 10.1016/j.resp.2009.04.005. Epub 2009 Apr 14.
Clinical trial NCT00849537: The Effect of Intravitral Injection of Triamcinolone Combined With Cataract Surgery (Phacoemulsification) on Diabetic Macular Edema and Diabetic Retinopathy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Diabetic Retinopathy
Keywords: Triamcinolon
Cataract
Diabetic retinopathy
non-proliferative retinopathy
Lead sponsor: Shahid Beheshti University of Medical Sciences
Sponsor class: OTHER
First posted: 2009-02-24
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this study, regressed proliferative diabetic retinopathy, very severe, severe and moderate non-prolifrative diabetic retinopathy patients who were going to have a cataract surgery, underwent a complete eye examination, OCT, FAG and color photography 2 weeks prior to their operation. All patients divided in two: 1) control group (Phyco,PCIOL), 2) triamcinolone treatment group (Phaco with PCIOL+IVT). One month after surgery a complete eye examination will be done especially; IOP and endophthalmitis. A 6 month follow-up will be done for these two groups and diabetic retinopathy progression will be checked.


Eligibility criteria: Inclusion Criteria:

* Diabetic patients with non-proliferative diabetic retinopathy and regressed PDR

Exclusion Criteria:

* Uncontrolled HTN
* History of glaucoma
* Active PDR
* NVI
* TRD
* Any ophthalmic operation
* Renal problem(cr\>3)
* CVA
* Uveitis

Primary outcomes:
measure: Macula diameter
timeFrame: 6th week, 3, 6 months
Secondary outcomes:
measure: Diabetic retinopathy
timeFrame: 6th weeks, 3 and 6 months later
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Ophthalmic Research Centre
city: Tehran
country: Iran, Islamic Republic of
facility: Siamak Moradian,MD
city: Tehran
country: Iran, Islamic Republic of
Study officials:
affiliation: Shaheed Beheshti University Of Medical Science
name: Dr. Siamak Moradian, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01430637: Studying Genes in Samples From Younger Patients With Desmoplastic Small Round Cell Tumor Registered on COG-D9902 or COG-ABTR01B1
Official title: Comprehensive Genome Sequencing of Desmoplastic Small Round Cell Tumors
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sarcoma
Keywords: childhood desmoplastic small round cell tumor
metastatic childhood soft tissue sarcoma
nonmetastatic childhood soft tissue sarcoma
recurrent childhood soft tissue sarcoma
recurrent adult soft tissue sarcoma
stage I adult soft tissue sarcoma
stage II adult soft tissue sarcoma
stage III adult soft tissue sarcoma
stage IV adult soft tissue sarcoma
adult desmoplastic small round cell tumor
Lead sponsor: Children's Oncology Group
Sponsor class: NETWORK
Collaborators: name: National Cancer Institute (NCI)
First posted: 2011-09-08
Enrollment: 20
Sex: ALL
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients registered on COG-D9902 or COG-ABTR01B1.

Brief summary: RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is studying genes in samples from younger patients with desmoplastic small round cell tumor registered on COG-D9902 or COG-ABTR01B1.

Detailed description: OBJECTIVES:

* To perform whole-exome sequencing on desmoplastic small round cell tumor (DSRCT) samples and their available matched normal samples to identify novel mutations, single nucleotide polymorphisms, or copy number changes associated with these tumors.
* To identify regions of interest that may be involved in the pathogenesis (including the region of EWSR1-WT1 translocation) from the whole-exome sequencing and perform detailed resequencing and transcriptone sequencing to further define the molecular aberrations at the RNA level.

OUTLINE: This is a multicenter study.

Archived tumor tissue samples are analyzed for DNA sequencing, effects of RNA on gene expression levels, novel RNA isoforms, splice variants, and translocations.

Eligibility criteria: DISEASE CHARACTERISTICS:

* Tumor and blood samples from patients registered on COG-D9902 or COG-ABTR01B1 obtained from the Cooperative Human Tissue Network (CHTN) and the Children's Oncology Group (COG) tumor banks
* Matched normal samples

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* Not specified

Primary outcomes:
measure: Identification of novel mutations, single nucleotide polymorphisms, and copy number changes associated with DSRCT
measure: Identification of genomic regions involved in pathogenesis of DSRCT
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Phoenix Children's Hospital
name: Pooja Hingorani, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01073137: Noninvasive Blood Glucose Monitoring Using Otoacoustic Emissions
Official title: Noninvasive Blood Glucose Monitoring Using Otoacoustic Emissions
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Diabetes
Keywords: diabetes
Lead sponsor: Portland VA Medical Center
Sponsor class: FED
First posted: 2010-02-23
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Diabetese subjects with no hearing impairement.

Brief summary: The purpose of the research is to determine whether a noninvasive hearing test may be used to predict blood glucose in people with diabetes.

Detailed description: Participation in the study will involve listening to sounds through earphones while blood glucose levels are measured by taking blood samples using a lancet. During the study, blood glucose levels will be increased by drinking a beverage containing sugar.

Up to five visits to the NCRAR will be needed over a six-month period to complete the study. Each visit lasts either two or four hours, and will be scheduled at your convenience. You will be paid $20 for the first 2-hour screening visit and $50 for each 4-hour visit. You will be paid $30 if you are selected to participate in a 2-hour Attention Correlation Test that a sub-set of 10 participants will complete.

Eligibility criteria: Inclusion Criteria:

* 18 years or older
* Diabetes
* Normal hearing
* Hemoglobin A1C of 5.5-8%

Exclusion Criteria:

* Volunteers may not participate if they have peripheral neuropathy

  * visual impairment due to diabetic retinopathy
  * organ failure (kidney, liver heart, or lungs)
  * severe or unstable cardiovascular disease
  * active alcohol or drug abuse
  * schizophrenia
  * bipolar disorder
  * active major depressive disorder
  * active foot ulcerations
  * active viral or other infections such as HIV
  * hepatitis, or pneumonia
  * serious renal
  * cardiac or cognitive dysfunction.

Primary outcomes:
measure: Otoacoustic emissions change with blood sugar levels
timeFrame: One 2-hour screening visit, and on 4-hour visit
Secondary outcomes:
Other outcomes:
Locations:
city: Portland
country: United States
facility: Portland VA Medical Center
state: Oregon
Study officials:
affiliation: Oregon Health and Science University
name: Eric A Wan, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02962037: Are Patients Suffering From DSPS Show Compromising in Everyday Functions and Abilities Before Handling the Disorder?
Official title: Are Patients Suffering From DSPS Show Compromising in Everyday Functions and Abilities (Attention and Concentration, Mood and Fatigue) Before Handling the Disorder? And Whether the Treatment Fixes the Disorder?
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Delayed Sleep Phase Syndrome
Lead sponsor: Assuta Medical Center
Sponsor class: OTHER
First posted: 2016-11-11
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether the known treatment for DSPS also improve the cognitive ability and mood of the patients.

Detailed description: Every participant will take a few test and tasks that are going to test his cognitive ability and mood before treatment in 08:00 and 20:00, and again the same tests at the same hours after the treatment.

Eligibility criteria: Inclusion Criteria:

* diagnosed with DSPS

Exclusion Criteria:

* attention deficit hyperactivity disorder - diagnosed, affective disorder- diagnosed

Primary outcomes:
measure: Sleep patterns
timeFrame: 1 week
measure: Melatonin secretion
timeFrame: 12 hours
measure: Brief Symptom Inventory
timeFrame: 1 day
measure: Epworth Sleepiness Scale
timeFrame: 1 day
measure: Karolinska Sleepiness Scale
timeFrame: 1 day
measure: Continuous Performance Test 3
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05598437: Prevalence of Different Etiologies of Ocular Dryness in Patients Previously Diagnosed With Dry Eye Disease in A Sample of Egyptian Patients
Official title: Search Protocol 1. Study a-Proposed Study Title: Prevalence of Different Etiologies of Ocular Dryness in Patients Previously Diagnosed With Dry Eye Disease in A Sample of Egyptian Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Dryness
Dry Eye Syndromes
Meibomian Gland Dysfunction
Keywords: Dry eye disease
Lead sponsor: Cairo University
Sponsor class: OTHER
Collaborators: name: Cairo University
First posted: 2022-10-28
Enrollment: 200
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Egyptian people between 20 and 70 years old coming to outpatient clinic BUT\< 10 seconds.. No previous surgery. No previous trauma. Not using eye drops in the last 3 months.

Brief summary: Proposed Study Title: Prevalence of Different Etiologies of Ocular Dryness in Patients Previously Diagnosed with Dry Eye

Detailed description: Dry eye disease (DED) is a common chronic multifactorial condition of the ocular surface characterized by failure to produce high quality or sufficient amounts of tears to moisturize the eyes (1) DED can be categorized as "dry eye with reduced tear production (aqueous deficient) and dry eye with increased evaporation of the tear film known as the hyperevaporative type... Although 10% of individuals have aqueous deficient DED, more than 80% have either the hyperevaporative type related to meibomian gland dysfunction (MGD), or a combination of

Eligibility criteria: Inclusion Criteria:

* Egyptian people between 20 and 70 years old coming to outpatient clinic BUT\< 10 seconds.. No previous surgery. No previous trauma. Not using eye drops in the last 3 months.

Exclusion Criteria:

Diabetic patients. Patients with rheumatological diseases that may affect ocular surface as RA.

Primary outcomes:
measure: Meibomian gland dysfunction
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Cairo university
city: Giza
country: Egypt
facility: Cairo university
Study officials:
References:
Clinical trial NCT05584215: Cognitive Behavioural Therapy-Informed Groups for Psychosis
Official title: Cognitive Behavioural Therapy-Informed Groups for Psychosis
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Psychosis
Keywords: cognitive behavioral therapy
Lead sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sponsor class: OTHER
First posted: 2022-10-18
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a feasibility study of cognitive behavioural therapy-informed groups for psychiatric inpatients with positive symptoms of psychosis.

Detailed description: The majority of inpatients at Parkwood Institute Mental Health have symptoms of psychosis. In line with Health Quality Ontario standards for the treatment of psychosis, the investigators would like to implement and evaluate cognitive behavioural therapy for psychosis (CBTp) informed groups. The feasibility, acceptability, and preliminary efficacy of CBTp groups for inpatients will be examined. Pragmatically, the investigators propose to undergo training in CBTp, implement empirically-supported CBTp protocols developed for inpatients, track outcomes, and publish our findings. The investigators would also incorporate patient feedback to improve future iterations of the protocol. Such an undertaking would build research capacity in front line staff by encouraging engagement in CBTp group training, survey design, participant screening, data collection, analyses, and dissemination of findings.

Eligibility criteria: Inclusion Criteria:

* Can read/write in English
* Has positive symptoms of psychosis that are distressing to them

Exclusion Criteria:

* Inability to tolerate group participation

Primary outcomes:
measure: Clinical Outcomes in Routine Evaluation 10 (CORE-10)
timeFrame: Up to 2 months
measure: Process of Recovery Questionnaire (QPR)
timeFrame: Up to 2 months
Secondary outcomes:
measure: The Positive and Negative Syndrome Scale (PANSS) - Positive Symptoms
timeFrame: Up to 2 months
Other outcomes:
measure: Satisfaction Questionnaire
timeFrame: Up to 2 months
Locations:
Study officials:
affiliation: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
name: Serena Wong, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00774215: Evaluation of the Avaulta Procedure for the Correction of Pelvic Organ Prolapse - Results at 1 Year
Official title: Retrospective Cohort of the Avaulta Vaginal Mesh Procedure as a Treatment of Pelvic Organ Prolapse
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pelvic Organ Prolapse
Keywords: Pelvic Organ Prolapse
Cystocele
Rectocele
Enterocele
Synthetic Mesh
Vaginal Mesh
Transobturator
Lead sponsor: Atlantic Health System
Sponsor class: OTHER
First posted: 2008-10-17
Enrollment: 103
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients who underwent surgery with the Avaulta synthetic mesh kit from 1/06 - 4/08.

Brief summary: This study is a 1 year review of all patients who had surgery to correct pelvic organ prolapse (i.e. cystocele, rectocele, enterocele) using the Avaulta synthetic mesh kit.

Detailed description: This is a retrospective cohort analysis of all patients who experienced vaginal prolapse and were operated on with the Avaulta synthetic vaginal mesh "kit" from January 2006 to April 2007. The Avaulta synthetic mesh is composed of polypropylene which is a monofilament. The objective of this trial is to compare patients objectively and subjectively at least one year after placement of the Avaulta synthetic vaginal mesh in terms of prolapse symptoms.

This data will be compared to pre-operative data already collected for these patients as a part of their routine surgical work-up. Mesh-related complications will be quantified, including erosions, new-onset pain, and infections. Success and anatomic recurrence rates will be recorded as well

Eligibility criteria: Inclusion Criteria:

* All patiAll patients who underwent surgery with the Avaulta synthetic mesh kit from 1/06 - 4/08.

Exclusion Criteria:

* Unable to give informed consent to participate

Primary outcomes:
measure: Anatomical success rates 1 year after surgery to correct pelvic organ prolapse with the Avaulta synthetic mesh kit
timeFrame: 1 year post operatively
Secondary outcomes:
measure: Mesh complications 1 year after surgery with the Avaulta synthetic mesh kit
timeFrame: 1 year
Other outcomes:
Locations:
city: Morristown
country: United States
facility: Atlantic Health System - Division of Urogynecology
state: New Jersey
Study officials:
References:
citation: Rudnicki M, Laurikainen E, Pogosean R, Kinne I, Jakobsson U, Teleman P. Anterior colporrhaphy compared with collagen-coated transvaginal mesh for anterior vaginal wall prolapse: a randomised controlled trial. BJOG. 2014 Jan;121(1):102-10; discussion 110-1. doi: 10.1111/1471-0528.12454. Epub 2013 Oct 1.